Advertisement

Science China Life Sciences

, Volume 62, Issue 9, pp 1138–1143 | Cite as

Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention

  • Mengxin Tian
  • Yinghong Shi
  • Weiren Liu
  • Jia FanEmail author
Review From CAS & CAE Members
  • 83 Downloads

Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, leading to 74.6 thousand deaths annually. The prognosis of HCC over the last few decades has remained unsatisfactory, and over half of patients with early-stage HCC develop recurrence by the time of follow-up. Immunotherapeutic intervention has emerged as a novel, effective treatment to delay the progression of aggressive tumors and suppress tumor recurrence and metastasis. However, few clinical immunotherapy trials have been conducted in HCC patients, and there is an unmet need for novel therapeutic strategies. The combination of conventional treatments with specific immunotherapeutic approaches may dramatically improve the efficacy of HCC treatment and the clinical outcome of HCC patients. In this review, we briefly summarize immunotherapy strategies and discuss new advances in combined immunotherapeutic approaches for the treatment of patients with liver cancer.

hepatocellular carcinoma immunotherapy immune checkpoint inhibitor strategy combination therapy 

Notes

Compliance and ethics The author(s) declare that they have no conflict of interest.

References

  1. Abou-Alfa, G.K., Meyer, T., Cheng, A.L., El-Khoueiry, A.B., Rimassa, L., Ryoo, B.Y., Cicin, I., Merle, P., Chen, Y.H., Park, J.W., et al. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 379, 54–63.CrossRefGoogle Scholar
  2. Alnaggar, M., Lin, M., Mesmar, A., Liang, S., Qaid, A., Xu, K., Chen, J., Niu, L., and Yin, Z. (2018). Allogenic natural killer cell immunotherapy combined with irreversible electroporation for stage IV hepatocellular carcinoma: survival outcome. Cell Physiol Biochem 48, 1882–1893.CrossRefGoogle Scholar
  3. Bollard, J., Miguela, V., Ruiz de Galarreta, M., Venkatesh, A., Bian, C.B., Roberto, M.P., Tovar, V., Sia, D., Molina-Sanchez, P., Nguyen, C.B., et al. (2017). Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma. Gut 66, 1286–1296.CrossRefGoogle Scholar
  4. Brown, S.D., Warren, R.L., Gibb, E.A., Martin, S.D., Spinelli, J.J., Nelson, B.H., and Holt, R.A. (2014). Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24, 743–750.CrossRefGoogle Scholar
  5. Burki, T.K. (2017). Palbociclib improves survival in advanced breast cancer. Lancet Oncol 18, e1.CrossRefGoogle Scholar
  6. Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, E.S., Laurent, A., Azoulay, D., et al. (2016). Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64, 2038–2046.CrossRefGoogle Scholar
  7. Chen, C.L., Pan, Q.Z., Zhao, J.J., Wang, Y., Li, Y.Q., Wang, Q.J., Pan, K., Weng, D.S., Jiang, S.S., Tang, Y., et al. (2016). PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology 5, e1176653.CrossRefGoogle Scholar
  8. Chen, L.T., Chen, M.F., Li, L.A., Lee, P.H., Jeng, L.B., Lin, D.Y., Wu, C.C., Mok, K.T., Chen, C.L., Lee, W.C., et al. (2012). Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection. Ann Surg 255, 8–17.CrossRefGoogle Scholar
  9. Chen, Y., Ramjiawan, R.R., Reiberger, T., Ng, M.R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E.C., Reddy, T.P., et al. (2015). CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61, 1591–1602.CrossRefGoogle Scholar
  10. Cui, J., Wang, N., Zhao, H., Jin, H., Wang, G., Niu, C., Terunuma, H., He, H., and Li, W. (2014). Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 134, 342–351CrossRefGoogle Scholar
  11. Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., Davis, J.L., Hughes, M.S., Heller, T., ElGindi, M., et al. (2017). Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66, 545–551.CrossRefGoogle Scholar
  12. El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Kim, T.Y., Choo, S.P., Trojan, J., Welling 3rd, T.H., et al. (2017). Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502.CrossRefGoogle Scholar
  13. Forner, A., Reig, M., and Bruix, J. (2018). Hepatocellular carcinoma. Lancet 391, 1301–1314.CrossRefGoogle Scholar
  14. Gianni, L., Bisagni, G., Colleoni, M., Del Mastro, L., Zamagni, C., Mansutti, M., Zambetti, M., Frassoldati, A., De Fato, R., Valagussa, P., et al. (2018). Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study. Lancet Oncol 19, 249–256.CrossRefGoogle Scholar
  15. Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J.L., Hodous, B., Brooijmans, N., et al. (2015). First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discovery 5, 424–437.CrossRefGoogle Scholar
  16. Heo, J., Reid, T., Ruo, L., Breitbach, C.J., Rose, S., Bloomston, M., Cho, M., Lim, H.Y., Chung, H.C., Kim, C.W., et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 19, 329–336.CrossRefGoogle Scholar
  17. Horwitz, E., Stein, I., Andreozzi, M., Nemeth, J., Shoham, A., Pappo, O., Schweitzer, N., Tornillo, L., Kanarek, N., Quagliata, L., et al. (2014). Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discovery 4, 730–743.CrossRefGoogle Scholar
  18. Inada, Y., Mizukoshi, E., Seike, T., Tamai, T., Iida, N., Kitahara, M., Yamashita, T., Arai, K., Terashima, T., Fushimi, K., et al. (2019). Characteristics of immune response to tumor-associated antigens and immune cell profile in patients with hepatocellular carcinoma. Hepatology 69, 653–665.CrossRefGoogle Scholar
  19. Janjigian, Y.Y., Bendell, J., Calvo, E., Kim, J.W., Ascierto, P.A., Sharma, P., Ott, P.A., Peltola, K., Jaeger, D., Evans, J., et al. (2018). CheckMate-032 study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer. J Clin Oncol 36, 2836–2844.CrossRefGoogle Scholar
  20. Le, D.T., Durham, J.N., Smith, K.N., Wang, H., Bartlett, B.R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B.S., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413.CrossRefGoogle Scholar
  21. Lee, J.H., Lee, J.H., Lim, Y.S., Yeon, J.E., Song, T.J., Yu, S.J., Gwak, G.Y., Kim, K.M., Kim, Y.J., Lee, J.W., et al. (2015). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148, 1383–1391.e6.CrossRefGoogle Scholar
  22. Lee, J.H., Tak, W.Y., Lee, Y., Heo, M.K., Song, J.S., Kim, H.Y., Park, S.Y., Bae, S.H., Lee, J.H., Heo, J., et al. (2017). Adjuvant immunotherapy with autologous dendritic cells for hepatocellular carcinoma, randomized phase II study. Oncoimmunology 90, e1328335.CrossRefGoogle Scholar
  23. Liu, C.Q., Xu, J., Zhou, Z.G., Jin, L.L., Yu, X.J., Xiao, G., Lin, J., Zhuang, S.M., Zhang, Y.J., and Zheng, L. (2018). Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 119, 80–88.CrossRefGoogle Scholar
  24. Llovet, J.M., Sala, M., Castells, L., Suarez, Y., Vilana, R., Bianchi, L., Ayuso, C., Vargas, V., Rodes, J., and Bruix, J. (2000). Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 31, 54–58.CrossRefGoogle Scholar
  25. Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., and Gores, G. (2016). Hepatocellular carcinoma. Nat Rev Dis Primers 2, 16018.CrossRefGoogle Scholar
  26. Long, G.V., Atkinson, V., Lo, S., Sandhu, S., Guminski, A.D., Brown, M.P., Wilmott, J.S., Edwards, J., Gonzalez, M., Scolyer, R.A., et al. (2018). Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol 19, 672–681.CrossRefGoogle Scholar
  27. Mazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006). Prevention ofhepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44, 1543–1554.CrossRefGoogle Scholar
  28. Mazzolini, G., Alfaro, C., Sangro, B., Feijoó, E., Ruiz, J., Benito, A., Tirapu, I., Arina, A., Sola, J., Herraiz, M., et al. (2005). Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol 23, 999–1010.CrossRefGoogle Scholar
  29. McGranahan, N., Furness, A.J.S., Rosenthal, R., Ramskov, S., Lyngaa, R., Saini, S.K., Jamal-Hanjani, M., Wilson, G.A., Birkbak, N.J., Hiley, C. T., et al. (2016). Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351, 1463–1469.CrossRefGoogle Scholar
  30. Motzer, R.J., Tannir, N.M., McDermott, D.F., Aren Frontera, O., Melichar, B., Choueiri, T.K., Plimack, E.R., Barthelemy, P., Porta, C., George, S., et al. (2018). Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 378, 1277–1290.CrossRefGoogle Scholar
  31. Murawski, M., Weeda, V.B., Maibach, R., Morland, B., Roebuck, D.J., Zimmerman, A., Casanova, M., Perilongo, G., Laithier, V., Kebudi, R., et al. (2016). Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor resectability and change outcome? lessons learned from the SIOPEL 2 and 3 studies. J Clin Oncol 34, 1050–1056.CrossRefGoogle Scholar
  32. O’Leary, B., Finn, R.S., and Turner, N.C. (2016). Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol 13, 417–430.CrossRefGoogle Scholar
  33. Qin, S., Bai, Y., Lim, H.Y., Thongprasert, S., Chao, Y., Fan, J., Yang, T.S., Bhudhisawasdi, V., Kang, W.K., Zhou, Y., et al. (2013). Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. J Clin Oncol 31, 3501–3508.CrossRefGoogle Scholar
  34. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348, 124–128.CrossRefGoogle Scholar
  35. Sangro, B., Gomez-Martin, C., de la Mata, M., Inarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J.I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013). A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59, 81–88.CrossRefGoogle Scholar
  36. Sawada, Y., Yoshikawa, T., Ofuji, K., Yoshimura, M., Tsuchiya, N., Takahashi, M., Nobuoka, D., Gotohda, N., Takahashi, S., Kato, Y., et al. (2016). Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. Oncoimmunology 5, e1129483.CrossRefGoogle Scholar
  37. Schulze, K., Imbeaud, S., Letouze, E., Alexandrov, L.B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015). Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47, 505–511.CrossRefGoogle Scholar
  38. Sherr, C.J. (2016). A new cell-cycle target in cancer—inhibiting cyclin D-dependent kinases 4 and 6. N Engl J Med 375, 1920–1923.CrossRefGoogle Scholar
  39. Shi, L., Lin, H., Li, G., Sun, Y., Shen, J., Xu, J., Lin, C., Yeh, S., Cai, X., and Chang, C. (2016). Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals. Cancer Lett 373, 45–56.CrossRefGoogle Scholar
  40. Shim, J.H., Jun, M.J., Han, S., Lee, Y.J., Lee, S.G., Kim, K.M., Lim, Y.S., and Lee, H.C. (2015). Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. Ann Surg 261, 939–946.CrossRefGoogle Scholar
  41. Sideras, K., Biermann, K., Verheij, J., Takkenberg, B.R., Mancham, S., Hansen, B.E., Schutz, H.M., de Man, R.A., Sprengers, D., Buschow, S. I., et al. (2017). PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology 6, e1273309.CrossRefGoogle Scholar
  42. Simonelli, M., Zucali, P., Santoro, A., Thomas, M.B., de Braud, F.G., Borghaei, H., Berlin, J., Denlinger, C.S., Noberasco, C., Rimassa, L., et al. (2016). Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma. Ann Oncol 27, 1782–1787.CrossRefGoogle Scholar
  43. Takayama, T., Sekine, T., Makuuchi, M., Yamasaki, S., Kosuge, T., Yamamoto, J., Shimada, K., Sakamoto, M., Hirohashi, S., Ohashi, Y., et al. (2000). Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356, 802–807.CrossRefGoogle Scholar
  44. Totoki, Y., Tatsuno, K., Covington, K.R., Ueda, H., Creighton, C.J., Kato, M., Tsuji, S., Donehower, L.A., Slagle, B.L., Nakamura, H., et al. (2014). Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat Genet 46, 1267–1273.CrossRefGoogle Scholar
  45. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571.CrossRefGoogle Scholar
  46. Ueno, M., Hayami, S., Shigekawa, Y., Kawai, M., Hirono, S., Okada, K., Tamai, H., Shingaki, N., Mori, Y., Ichinose, M., et al. (2015). Prognostic impact of surgery and radiofrequency ablation on single nodular HCC 5 cm: Cohort study based on serum HCC markers. J Hepatol 63, 1352–1359.CrossRefGoogle Scholar
  47. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M.H., Goldinger, S.M., et al. (2015). Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207–211.CrossRefGoogle Scholar
  48. Wang, H., Liu, A., Bo, W., Feng, X., Hu, Y., Tian, L., Zhang, H., and Tang, X. (2016). Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systematic review and meta-analysis. Digest Liver Dis 48, 1275–1282.CrossRefGoogle Scholar
  49. Yang, Y., Zhou, Y., Hou, J., Bai, C., Li, Z., Fan, J., Ng, I.O.L., Zhou, W., Sun, H., Dong, Q., et al. (2017). Hepatic IFIT3 predicts interferon-α therapeutic response in patients of hepatocellular carcinoma. Hepatology 66, 152–166.CrossRefGoogle Scholar
  50. Zhou, J., Liu, M., Sun, H., Feng, Y., Xu, L., Chan, A.W.H., Tong, J.H., Wong, J., Chong, C.C.N., Lai, P.B.S., et al. (2018). Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut 67, 931–944.CrossRefGoogle Scholar

Copyright information

© Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Mengxin Tian
    • 1
    • 2
  • Yinghong Shi
    • 1
    • 2
  • Weiren Liu
    • 1
    • 2
  • Jia Fan
    • 1
    • 2
    • 3
    Email author
  1. 1.Department of Liver Surgery & Transplantation Center, Liver Cancer Institute, Zhongshan HospitalFudan UniversityShanghaiChina
  2. 2.Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of EducationShanghaiChina
  3. 3.Institute of Biomedical SciencesFudan UniversityShanghaiChina

Personalised recommendations